Back to Best of AC2017 Session - Second-Line Therapy for Metastatic Renal Cell Carcinoma: Making Strategic Choices - On-Demand
Best of AC2017 Session - Second-Line Therapy for Metastatic Renal Cell Carcinoma: Making Strategic Choices - On-Demand

Best of AC2017 Session - Second-Line Therapy for Metastatic Renal Cell Carcinoma: Making Strategic Choices - On-Demand

This session will explore new therapeutic options for the second-line treatment of metastatic renal cell carcinoma. As treatment options have expanded, the preferred second-line agent is being debated. Evidence for targeted therapies and immunotherapy in the second-line setting will be reviewed, with discussion of the advantages and disadvantages of therapy. This session will help the oncology pharmacist determine a strategy for selecting and recommending a second-line treatment option for a patient with metastatic renal cell carcinoma.

 

Content Area: Patient Management & Therapeutics

Product Details

This session is from 2017 HOPA Annual Conference

Speakers:

Jocelyn Mohs, PharmD BCOP; Anne Spengler, PharmD BCOP; Rebecca Greene, PharmD BCOP

 

Learning Objectives:

1.      Identify controversies surrounding second-line therapy for metastatic renal cell carcinoma.

2.      Evaluate the evidence for use of targeted therapy and immunotherapy for second-line therapy.

3.      Apply evidence to selected second-line therapy based on patient specific factors.

 

  • List Price: $35.00 USD
  • Member Price: $25.00 USD
Join and Save!
Log into see if you qualify for a lower price.
HOPA members save $10.00 USD or more!
Become a member